MicroRNA-223 controls the expression of histone deacetylase 2: a novel axis in COPD by Leuenberger, Caroline et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
MicroRNA-223 controls the expression of histone deacetylase 2: a novel axis
in COPD
Leuenberger, Caroline; Schuoler, Claudio; Bye, Hannah; Mignan, Célia; Rechsteiner, Thomas; Hillinger,
Sven; Opitz, Isabelle; Marsland, Benjamin; Faiz, Alen; Hiemstra, Pieter S; Timens, Wim; Camici,
Giovanni G; Kohler, Malcolm; Huber, Lars C; Brock, Matthias
Abstract: Reduced activity of histone deacetylase 2 (HDAC2) has been described in patients with chronic
obstructive pulmonary disease (COPD), but the mechanisms resulting in decreased expression of this im-
portant epigenetic modifier remain unknown. Here, we employed several in vitro experiments to address
the role of microRNAs (miRNAs) on the regulation of HDAC2 in endothelial cells. Manipulation of
miRNA levels in human pulmonary artery endothelial cells (HPAEC) was achieved by using electropora-
tion with anti-miRNAs and miRNA mimics. Target prediction software identified miR-223 as a potential
repressor of HDAC2. In subsequent stimulation experiments using inflammatory cytokines known to be
increased in patients with COPD, miR-223 was found to be significantly induced. Functional analy-
sis demonstrated that overexpression of miR-223 decreased HDAC2 expression and activity in HPAEC.
Conversely, HDAC2 expression and activity was preserved in anti-miR-223-treated cells. Direct miRNA-
target interaction was confirmed by reporter gene assay. In a next step, reduced expression of HDAC2
was found to increase the levels of the chemokine fractalkine (CX3CL1). In vivo studies confirmed ele-
vated expression levels of miR-223 in mice exposed to cigarette smoke and in emphysematous lung tissue
from LPS-treated mice. Moreover, a significant inverse correlation of miR-223 and HDAC2 expression
was found in two independent cohorts of COPD patients. These data emphasize that miR-223, the most
prevalent miRNA in COPD, controls expression and activity of HDAC2 in pulmonary cells, which, in
turn, might alter the expression profile of chemokines. This pathway provides a novel pathogenic link
between dysregulated miRNA expression and epigenetic activity in COPD. KEY MESSAGES: Histone
deacetylase 2 is directly targeted by miR-223. Levels of miR-223 are induced by interleukin-1￿ and tu-
mor necrosis factor-￿. miR-223 controls the expression of fractalkine by targeting histone deacetylase 2.
miR-223 levels are increased in COPD mouse models. miR-223 levels inversely correlate with HDAC2
expression in COPD patients.
DOI: https://doi.org/10.1007/s00109-016-1388-1
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-123276
Accepted Version
Originally published at:
Leuenberger, Caroline; Schuoler, Claudio; Bye, Hannah; Mignan, Célia; Rechsteiner, Thomas; Hillinger,
Sven; Opitz, Isabelle; Marsland, Benjamin; Faiz, Alen; Hiemstra, Pieter S; Timens, Wim; Camici, Gio-
vanni G; Kohler, Malcolm; Huber, Lars C; Brock, Matthias (2016). MicroRNA-223 controls the expression
of histone deacetylase 2: a novel axis in COPD. Journal of Molecular Medicine, 94(6):725-734.
DOI: https://doi.org/10.1007/s00109-016-1388-1
2
microRNA-223 controls the expression of histone deacetylase 2: a novel axis in COPD 
 
Caroline Leuenberger1, Claudio Schuoler1,2, Hannah Bye1, Célia Mignan1, Thomas Rechsteiner1, Sven Hillinger3, 
Isabelle Opitz3, Benjamin Marsland4, Alen Faiz5, Pieter S. Hiemstra6, Wim Timens7, Giovanni G. Camici8, 
Malcolm Kohler1, Lars C. Huber1,*, and Matthias Brock1,* 
 
1) Division of Pulmonology University Hospital Zurich, University of Zurich, Zurich, Switzerland 
2) Institute of Veterinary Physiology, University of Zurich and Zurich Center for Integrative Human 
Physiology (ZIHP), Zurich, Switzerland 
3) Division of Thoracic Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland 
4) Faculty of Biology and Medicine, University of Lausanne, Service de Pneumologie, Centre Hospitalier 
Universitaire Vaudois (CHUV), Lausanne, Switzerland 
5) Department of Pulmonary Diseases, University Medical Center Groningen, University of Groningen, 
Groningen, The Netherlands 
6) Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, The Netherlands  
7) Department of Pathology and Medical Biology, University Medical Center Groningen, University of 
Groningen, Groningen, the Netherlands 
8) Center for Molecular Cardiology, Division of Cardiology, University Hospital of Zurich, University of 
Zurich, Zurich, Switzerland 
 
*) These authors share senior authorship 
 
Corresponding author: Matthias Brock, Division of Pulmonology University Hospital Zurich, Wagistrasse 14, 
8952 Schlieren, Switzerland. e-Mail: matthias.brock@uzh.ch, phone: 0041 44 556 31 60. 
 
Keywords: chronic obstructive pulmonary disease, microRNA, inflammation, histone deacetylase 2 
  
	 2 
Abstract 
Reduced activity of Histone Deacetylase 2 (HDAC2) has been described in patients with chronic obstructive 
pulmonary disease (COPD) but the mechanisms resulting in decreased expression of this important epigenetic 
modifier remain unknown. Here we employed several in vitro experiments to address the role of microRNAs 
(miRNAs) on the regulation of HDAC2 in endothelial cells. Manipulation of miRNA levels in human pulmonary 
artery endothelial cells (HPAEC) was achieved by using electroporation with anti-miRNAs and miRNA mimics. 
Target prediction software identified miR-223 as a potential repressor of HDAC2. In subsequent stimulation 
experiments using inflammatory cytokines known to be increased in patients with COPD miR-223 was found to be 
significantly induced. Functional analysis demonstrated that overexpression of miR-223 decreased HDAC2 
expression and activity in HPAEC. Conversely, HDAC2 expression and activity was preserved in anti-miR-223 
treated cells. Direct miRNA-target interaction was confirmed by reporter gene assay. In a next step, reduced 
expression of HDAC2 was found to increase the levels of the chemokine Fractalkine (CX3CL1). In vivo studies 
confirmed elevated expression levels of miR-223 in mice exposed to cigarette smoke and in emphysematous lung 
tissue from LPS treated mice. Moreover, a significant inverse correlation of miR-223 and HDAC2 expression was 
found in two independent cohorts of COPD patients. These data emphasize that miR-223, the most prevalent 
miRNA in COPD, controls expression and activity of HDAC2 in pulmonary cells, which, in turn, might alter the 
expression profile of chemokines. This pathway provides a novel pathogenic link between dysregulated miRNA 
expression and epigenetic activity in COPD. 
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Introduction 
 
Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow limitation, chronic 
inflammation and emphysematous destruction of the lung tissue. The social and economic burden of COPD is 
substantial: COPD affects about 10% of the world’s population and, according to prediction models, will become 
the third leading cause of death by 2020 [1]. The pathogenesis of COPD, however, is incompletely understood. 
Cigarette smoke and other noxious particles are important risk factors by inducing the release of inflammatory 
mediators such as tumor necrosis factor (TNF) α [2], interleukin 1 (IL-1) β [3] and chemokines [4]. These factors, 
among other mechanisms, lead to infiltration of the airway epithelium with inflammatory cells, chronic bronchial 
inflammation and consecutive tissue destruction [5]. 
 
The expression pattern of major transcription factors downstream of inflammatory cytokines appears to be 
epigenetically changed. Modifications of histone proteins are – together with DNA methylation – the most 
important group of epigenetic alterations [6]. Of these, the balance between histone acetylation and deacetylation 
is arguably the most investigated. Decreased histone deacetylase (HDAC) activity allows the acetylated chromatin 
to be unbound to histones. In turn, transcription factors can access the chromatin and the mRNA of distinct 
inflammatory cytokines and chemokines can be produced [7]. 
 
In lung tissue obtained from patients with COPD, the activity of HDAC and especially HDAC2 has been found 
decreased. Moreover, HDAC2 activity was discovered to be negatively correlated with disease severity [8]. This is 
an interesting observation with major impact on the pathogenic understanding and novel therapeutic approaches to 
patients with COPD. To date, however, it remains unclear which mechanisms are responsible for the reduced 
expression of HDAC2 in COPD.  
 
Of interest, HDAC2 has previously been described to be influenced by micoRNAs (miRNAs) in liver cancer [9]. 
miRNAs are endogenously expressed small non-coding RNA molecules of 20-22nt that bind to complementary 
sequences within the 3’ untranslated region (UTR) of target mRNAs in order to repress their expression [10]. It is 
assumed that more than 60% of the human genome is regulated by miRNAs [11]. Conversely, the role of miRNAs 
in the pathogenesis of COPD is only poorly understood and the potential impact of miRNAs on the expression of 
HDAC2, a key player in the pathogenesis of COPD [8], and on the inflammatory response in human pulmonary 
cells remains unknown.  
 
The present study was designed to test the hypothesis that HDAC2 is regulated via miRNA and the potential of 
these miRNAs to maintain a chronic inflammatory response in COPD. 
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Material and Methods 
 
Human patient samples 
Lung tissue samples from COPD patients were obtained through our tissue bank in collaboration with the Division 
of Thoracic Surgery at the University Hospital of Zurich. In the present study patients with severe COPD that 
fulfilled the Global Initiative for COPD (GOLD) criteria were included. Written informed consent was obtained 
from all patients. The study design was approved by Zurich’s ethical review committee (KEK ZH-Nr 2014-0011). 
Validation of human gene expression was performed in patient samples derived from the GLUCOLD study cohort 
measured by Affymetrix Human Gene ST array and Affymetrix miRNA 2.0 array (GSE36221) [12-14]. 
 
Cell culture 
Human hepatocellular carcinoma (HepG2) cells were grown in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin and 1% HEPES. The HepG2 cell line was 
provided by the Department of Clinical Pharmacology and Toxicology of the University Hospital Zurich [15]. 
Human pulmonary artery endothelial cells (HPAEC, from Gibco, Life Technologies, Zug, Switzerland), human 
pulmonary artery smooth muscle cells (HPASMC, from Gibco), normal human bronchial epithelial cells (NHBEC 
from Lonza, Basel, Switzerland), and monocytes (Mono-Mac-6 cells from DSMZ, Braunschweig, Germany) were 
cultured according to the manufacturer’s instructions. All cells were incubated at 37°C in 5% CO2 atmosphere. 
When reaching 80% confluence, adherent cells were trypsinized in trypsin-EDTA and prepared for experiments. 
In all experiments performed, cells from passage 5-9 were used. Cells were seeded and allowed to settle for at least 
24 hours (h) before being transfected or stimulated. Cultured cells were stimulated either with IL-1β, TNF-α or a 
cocktail of both with a concentration of 10ng/ml, respectively. All stimulation agents are purchased from Sigma 
Aldrich (Buchs, Switzerland). Stimulation was performed over different time points (24h, 48h, or 72h). 
 
Experimental in vivo models 
To induce lung emphysema and COPD in an animal model, mice were exposed to cigarette smoke from research 
cigarettes (1R4F, University of Kentucky, USA) for 5 days per week as described elsewhere [16]. After 3 weeks 
mice were euthanized and total RNA including miRNAs from lung tissue was isolated. In the second model, mice 
were treated either with lipopolysaccharide (LPS) or control phosphate buffer saline (PBS) inhalants as described 
before to induce elastase which leads to the development of lung emphysema [17]. Paraffin embedded mouse lung 
tissue samples were used for quantification of miRNAs. Both animal models were provided by our collaborators 
Benjamin Marsland and Giovanni Camici. The animal experimentation was approved by the local Canton’s 
Veterinary office. 
 
Molecular biology methods 
A detailed description of several molecular biology methods including plasmid construction, reporter gene assay, 
transfection, RNA isolation from tissue, cultured cells, supernatants, and paraffin blocks, quantification of gene 
expression and mature miRNAs, Western Blot, and HDAC/HDAC2 Glo assay can be found in the electronic 
supplementary material of this article. 
 
Data processing 
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All data are presented as the mean ± standard deviation (SD) of the indicated number of observations. Parametric 
or non-parametric distribution of data was determined using the Kolmogorov–Smirnov test. The paired or unpaired 
t-test (two-tailed) as a parametric method for testing was applied. Correlation analysis of normal distributed data 
was carried out using Pearson’s one-tailed correlation test reflecting the inverse relation of the expression of 
miRNAs and their associated targets. A p-value <0.05 was considered to be statistically significant (*≤0.05, 
**≤0.01, ***≤0.001). Statistical evaluations were performed with the software package GraphPad Prism Version 
5.0a (GraphPad Software, La Jolla, CA, USA).  
 
Results 
 
miR-223 directly targets HDAC2 
To address the question whether the observed reduction of HDAC2 protein in COPD patients could be mediated 
by the action of miRNAs, DICER1, a key protein in miRNA processing, was silenced in HPAEC using siRNA 
directed against DICER1. As shown in Figure 1, levels of DICER1 mRNA were significantly decreased after 24h 
(reduction of 72%), 48h (reduction of 55.3%), and 72h (reduction of 46.3%). Simultaneously, a trend toward 
increased levels of HDAC2 mRNA was observed after 24h (increase of 46.3%), 48h (increase of 21.2.%), and 72h 
(increase of 13.4%) of transfection. Moreover, when the activity of HDAC2 was assessed in HPAEC transfected 
for 24h with siRNA targeting DICER1 increased HDAC2 activity was found (increase to 1.44±0.53, p=0.101, 
Figure 1C). These data indicate a negative correlation between the expression levels of HDAC2 and DICER1 
implying a potential miRNA mediated mechanism of HDAC2 regulation in HPAEC. 
To determine which miRNA could be involved in HDAC2 repression, the following strategy was applied: (i) 
search for HDAC2 targeting miRNAs using computational algorithms [18], and (ii) focus on miRNAs previously 
associated with COPD. Based on this strategy three miRNAs were selected for further experiments: miR-182, 
miR-223 and, as a positive control, miR-145 that has been recently shown to target HDAC2 [9].  
Next, a luciferase reporter gene assay was used to investigate whether selected miRNAs directly interact with 
HDAC2. Reporter gene assay was carried out in HepG2 cells since these cells show high transfection efficacy. In 
addition, the interaction of miR-145 with HDAC2 was reported in HepG2 cells [9]. After transfection of luciferase 
constructs comprising the entire 3’UTR of HDAC2 and co-transfection of mimics of miR-145, miR-182, and miR-
223 luciferase activity was measured. As presented in Figure 2A, miR-145 significantly decreased luciferase 
activity of the construct encoding part 2 of HDAC2 (reduction to 0.77±0.18, p=0.046) whereas miR-223 
significantly repressed the activity of the construct encoding part 2 (reduction to 0.7±0.11, p=0.004) and part 3 
(reduction to 0.76±0.14, p=0.042). In contrast, miR-182 failed to decrease luciferase activity of any of the used 
constructs. These data indicate that the 3’UTR of HDAC2 contains functional seed matches of miR-223.  
 
Inflammatory cytokines induce the levels of miR-223  
To further investigate the role of miR-223 in COPD, the levels of miR-223 were quantified in pulmonary cells. As 
shown in Figure 3A, miR-223 levels could be measured and detected in HPASMC, NHBEC and HPAEC. Next, 
stimulation experiments were performed using cytokines that have been shown to be highly upregulated in COPD: 
IL-1β and TNFα [2, 3]. As demonstrated in Figure 3B, stimulation of HPAEC with IL-1β and TNFα increased the 
levels of miR-223 at all time points assessed. A significant upregulation of miR-223 was observed when HPAEC 
were stimulated with a cocktail of both (48h of stimulation: 2.84±1.06 fold, p=0.018; 72h of stimulation: 3.34±1.4 
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fold, p=0.02) as compared with unstimulated cells. A concomitant reduction of HDAC2 expression was detected 
when HPAEC were stimulated with a cocktail of IL-1β and TNFα (48h of stimulation: reduction to 0.63±0.11, 
p=0.002; 72h of stimulation: reduction to 0.81±0.17, p=0.07, Figure 3C). 
Next, the effect of cytokine stimulation on miR-223 levels was tested in other pulmonary cells and in monocytes. 
As shown in Figure 4A and 4B, stimulation of NHBEC and HPASMC with a cocktail of IL-1β and TNFα had no 
significant effect on miR-223 levels. The expression of miR-223 was significantly reduced in cell extracts of 
monocytes stimulated for 72h (reduction to 0.47±0.06, p<0.001, Figure 4C). Conversely, levels of miR-223 in the 
supernatants were found significantly increased (72h of stimulation: 1.7±0.46 fold, p=0.027, Figure 4D). 
These data demonstrate an endothelial cell specific cytokine-induced effect on miR-223 expression and, moreover, 
indicate that after cytokine treatment monocytes might release miR-223 in the extracellular space. 
 
miR-223 targets HDAC2 in HPAEC  
In a next step, we addressed the question whether miR-223 affects HDAC2 activity in HPAEC. After transfection 
with mimic or inhibitor of miR-223 HDAC2 activity was measured using a total HDAC or a specific HDAC2 
activity assay. Enforced expression of miR-223 resulted in a significant decrease of total HDAC (reduction to 
0.73±0.15, p=0.007) and HDAC2 activity (reduction to 0.69±0.18, p=0.007) as compared to scrambled transfected 
control cells (Figure 5A and 5B). Conversely, miR-223 inhibition led to increased total HDAC and HDAC2 
activity, however, without reaching statistical significance (Figure 5A and 5B).  
Regarding the expression of HDAC2, the same samples were analyzed for mRNA and protein levels of HDAC2. 
Transfection of HPAEC with miR-223 decreased the mRNA levels of HDAC2 to 0.86±0.15 (p=0.099) whereas 
miR-223 inhibition significantly increased mRNA levels of HDAC2 by 1.08±0.036 fold (p=0.007) as compared to 
control cells (Figure 5C and 5D). When protein levels of HDAC2 were analyzed, a significant decrease of HDAC2 
protein levels in miR-223 mimic transfected HPAEC was observed (reduction of 31±19%; p=0.021, Figure 5E). 
However, treatment with miR-223 inhibitor did not significantly influence the protein levels of HDAC2 (Figure 
5E). 
 
miR-223 induces the expression of Fractalkine via HDAC2 
To investigate the downstream effect of decreased HDAC2 activity, the mRNA levels of Fractalkine (CX3CL1), a 
chemokine expressed in endothelium, was assessed. As presented in Figure 6, a tendency to an increased 
expression of CX3CL1 in HPAEC transfected with miR-223 mimic was observed (Figure 6A). Similarly, 
treatment with anti-miR-223 led to a reduction of the mRNA level of CX3CL1 (Figure 6B).  
 
The role of miR-223 in vivo 
To confirm a dysregulated expression of miR-223 and its target HDAC2 in vivo, levels of miR-223 were measured 
in two experimental models of lung emphysema and COPD. First, mice were treated with LPS to induce lung 
inflammation and lung dysfunction [17] and the levels of miR-223 in lung tissue were found significantly 
upregulated as compared to saline-treated control mice (fold change of 1.97±0.12, p=0.006, Figure 7A). These 
data were confirmed in a small number of cigarette smoke exposed mice showing increased levels of miR-223 
(fold change of 1.63±0.62, n=3, Figure 7B). Moreover, human lung tissue from COPD patients was analyzed for 
miR-223 and HDAC2 expression. As presented in Figure 7C, a negative correlation between the expression of 
HDAC2 and the levels of miR-223 was found in patients with severe COPD (r=-0.532, p=0.046, n=11) collected 
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in our own tissue bank at the University Hospital Zurich. Similar results were obtained by analyzing patient 
samples from the databank of the GLUCOLD study [12] confirming a negative correlation between miR-223 and 
its target HDAC2 (r=-0.224, p=0.047, n=57, Figure 7D).  
 
Discussion 
 
In this study we provide evidence of a novel role for miR-223 in the pathogenesis of COPD. In detail, we show 
that (i) HDAC2 is directly targeted by miR-223 through binding to seed matches located in the 3’UTR of its 
mRNA transcript, (ii) total HDAC and HDAC2 activity is repressed in pulmonary endothelial cells in response to 
miR-223 overexpression, (iii) inflammatory cytokines known to be upregulated in COPD patients significantly 
induce the levels of miR-223 in endothelial cells, (iv) miR-223 is upregulated in experimental models of the 
disease, and that (v) the levels of miR-223 negatively correlate with the expression of HDAC2 in human lung 
tissue of COPD patients. These data further indicate that exposure to inflammation increases the levels of miR-223 
in the lung endothelium, which, through repression of HDAC2 and release of chemokines, might provide a 
positive inflammatory feedback loop in the pathogenesis of COPD. Taken together, our findings offer a novel 
mechanistic explanation for the previously described downregulation of HDAC2 in patients with COPD [8]. 
 
The expression and activity of HDAC2 was previously shown to be repressed in COPD patients and, as such, was 
found to be linked to disease severity [8]. While previous studies reported that nitration of tyrosine residues affect 
activity and stability of HDAC2 protein [19] and, moreover, that proteosomal imbalance might be of critical 
importance for these processes [20], the regulation of HDAC2 gene expression and associated pathways in COPD 
have not completely been unraveled. miRNAs have emerged as post-transcriptional gene silencers and we thus 
suggested their involvement in the decreased expression of HDAC2. In the context of COPD, miR-223 was 
recently described as the most upregulated miRNA in lung tissue of patients but its function has not been 
addressed [21]. Several miRNA target prediction algorithms identified potential binding sites of miRNAs that 
included seed matches for miR-223 in the 3’UTR of HDAC2 [18]. Moreover, the interaction of miRNAs with 
HDAC2 has previously been described in liver cancer where miR-145 was reported to act as tumor suppressor by 
targeting HDAC2 [9]. Due to these facts, the direct interaction of different miRNAs expressed in pulmonary cells 
and predicted to bind to the 3’UTR of HDAC2 was investigated. Subsequent reporter gene analysis confirmed the 
interaction of miR-145 and, as a novel finding, of miR-223 with the 3’UTR of HDAC2. We further identified seed 
matches located in the last two parts of the 3’UTR of HDAC2 indicating that these binding sites are targeted by 
miR-223.  
 
These results supported our hypothesis of a post-transcriptional regulation of HDAC2 by miR-223. In functional 
studies, we demonstrated that enforced expression of miR-223 in pulmonary endothelial cells leads to a significant 
reduction of protein levels and activity of HDAC2 in these cells. The mRNA levels, however, remained almost 
unchanged suggesting a miRNA-mediated inhibition of the translational process of the targeted transcript. Such a 
mechanistic interplay is frequently observed in the context of miRNA mediated gene regulation in human disease 
including pulmonary disorders [22]. Of note, when miR-223 was silenced using miRNA-inhibitors only minor 
effects could be observed on the expression levels of HDAC2. This finding might be explained as a consequence 
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of the low basal expression levels of miR-223 in unstimulated pulmonary endothelial cells derived from healthy 
donors, in which no additional suppression can be achieved by the antagonization of miR-223. 
 
Chronic inflammation in COPD is orchestrated by the activity of cytokines and chemokines, of which many can be 
detected at increased levels in the circulation of patients [5, 23]. In stimulation experiments using endothelial cells 
that, in vivo, reflect the first responders of the lungs to these proinflammatory signals, we found that IL-1β and 
TNFα significantly induced the levels of miR-223 in a time-dependent manner. These cytokines have been 
described as key inflammatory mediators in COPD [2, 3] and their activity in COPD patients might explain the 
significant upregulation of miR-223 levels in vivo as shown by Ezzie and colleagues [21]. Both cytokines are 
activators of the transcription factor nuclear factor kappa B (NF-κB). This signaling pathway has previously been 
proposed as link between cigarette-smoke induced inflammation, cytokine release and histone acetylation [24]. 
Our data support this notion (Figure 8) but at this moment it remains unclear whether the cytokine-triggered 
induction of miR-223 is a downstream event of the NF-κB signaling or, alternatively, acts as an independent 
factor. 
 
As a consequence of our stimulation experiments showing that miR-223 is most inducible in endothelial cells and 
the fact that these cells might act as pulmonary gatekeeper for inflammatory cells and cytokines and, as such, 
provide the interface between lung tissue and blood circulation the focus of this study was set on HPAEC. 
Endothelial cells secrete chemoattracants (e.g. CX3CL1) and might control inflammation within the lung tissue. 
The interaction between monocytes and endothelial cells is further highlighted by the fact that, upon stimulation 
with inflammatory cytokines, miR-223 is released from monocytes. Such mechanism might indicate exosomal 
transfer of miR-223 to endothelial cells as suggested previously [25] and, potentially, to other lung cells. 
Moreover, HPAEC are of further interest since endothelial dysfunction in smokers is well recognized [26, 27] and 
might contribute to altered inflammatory signaling. Since no effect on the expression levels of miR-223 has been 
observed in stimulation experiments using smooth muscle and bronchial epithelial cells, a cell-type specific effect 
of miR-223 induction upon cytokine stimulation cannot be excluded. As such, it remains elusive at the moment 
whether these mechanisms apply also to alveolar macrophages, in which reduced HDAC2 activity has initially 
been described [8]. 
 
As functional readout downstream of reduced HDAC2 activity, we observed an increase of CX3CL1 (Fractalkine) 
in HDAC2-deficient endothelial cells. Fractalkine is an important chemokine with a well-established role in the 
context of COPD and cigarette-smoke induced inflammation [4, 28]. As membrane-anchored protein, Fractalkine 
acts as an adhesion molecule on the surface of the endothelium, while its soluble form attracts inflammatory cells 
along a chemical gradient [29]. Here we identified a regulatory pathway in pulmonary endothelial cells involving 
inflammatory cytokines, miRNAs and HDAC2 that result in increased expression of Fractalkine (Figure 8). Our 
data show that stimulation of HPAEC with IL-1β and TNFα increases the expression levels of miR-223. The 
association between chronic inflammation and increased miR-223 levels was further emphasized in experimental 
models of COPD in which mice either treated with LPS or exposed to cigarette smoke showed elevated levels of 
miR-223 in their lungs when compared to control mice. Increased levels of miR-223 were further found to reduce 
both expression and activity of HDAC2 in vitro. Of note, a negative correlation of miR-223 levels with HDAC2 
expression was found in lung specimens of COPD patients from two independent tissue banks. According to Ito 
	 9 
and colleagues, less HDAC2 activity contributes to inflammatory processes in lung disease [8]. These results were 
confirmed here by showing the upregulation of Fractalkine following transfection of miR-223 mimics. This is a 
novel observation and highlights the importance of epigenetic modulation in the progression of COPD, which, as 
indicated by these experiments, might be mediated by the action of miRNAs [30].  
 
Conclusion 
To the best of our knowledge, this is the first report that has characterized the underlying mechanisms of 
noncoding RNAs involved in decreased HDAC2 activity in COPD patients. We provide evidence that one of the 
most prevalent miRNA in lung tissue (i.e. miR-223) directly targets HDAC2. Reduced HDAC2 activity, in turn, 
induces the expression of Fractalkine. Whether miR-223 can be used as a novel drug target in the treatment of lung 
inflammation in the context of COPD has to be addressed by further studies. 
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Figure Legends 
 
Fig. 1 Increased expression of histone deacetylase 2 (HDAC2) in DICER1-depleted endothelial cells 
Human pulmonary artery endothelial cells (HPAEC) transfected with small interfering RNA directed against the 
miRNA-processing enzyme DICER1 showed higher expression levels of HDAC2 as compared to scrambled 
control transfection. mRNA expression of DICER1 a) and HDAC2 b) after 24h, 48h, and 72h of transfection was 
quantified using qPCR (n=6). c) HDAC 2 activity after 24h of transfection was found to be significantly increased 
as assessed by enzymatic luminescent assay (n=5). Statistical analysis by paired Student’s t-test (*p<0.05, 
***p<0.001). 
 
Fig. 2 The 3’ UTR of HDAC2 is directly targeted by miRNAs 
The entire 3’UTR of HDAC2 was amplified out of genomic DNA, fragmented in three overlapping parts of 
approximately 2000bp length and subsequently cloned into a dual luciferase-expressing vector. a) Reporter gene 
studies showed that transfection of miR-223 mimic significantly lowered the relative luciferase activity of the 
constructs encoding part 2 and 3 as compared to scrambled (scr) control transfection. Enforced expression of miR-
145 resulted in significantly repressed luciferase expression of construct encoding part 2. Firefly and renilla 
luciferase activity was measured using dual luciferase assay (n=4). b) The predicted binding sites of miR-223 
within the 3’UTR of HDAC2 are presented. Statistical analysis by paired Student’s t-test (*p<0.05, **p<0.01). 
 
Fig. 3 Basal and cytokine-induced expression levels of miR-223 in pulmonary cells 
a) Expression levels of miR-223 in HPAEC, human pulmonary artery smooth muscle cells (HPASMC), and 
normal human bronchial epithelial cells (NHBEC) are shown (n=4). b) Stimulation of HPAEC with inflammatory 
cytokines interleukin-1β (IL-1β), tumor necrosis factor α (TNFα) or a cocktail of both further increased the 
expression levels of miR-223 (n=5). c) Stimulation of HPAEC with the cocktail resulted in a significant decrease 
of HDAC2 mRNA expression after 24h and 48h (n=5). The levels of miR-223 and HDAC2 were quantified using 
qPCR. Statistical analysis by paired Student’s t-test (*p<0.05, **p<0.01). 
 
Fig. 4 Cytokine-induced expression levels of miR-223 in pulmonary cells and monocytes 
Levels of miR-223 were assessed by qPCR in NHBEC (a, n=5) and in HPASMC (b, n=3) after stimulation with an 
inflammatory cytokine cocktail (IL-1β and TNFα) demonstrating no significant changes in miR-223 expression 
levels. Stimulation for 48h and 72h with the cytokine cocktail significantly decreased miR-223 expression levels 
in monocytes (c, n=5) whereas the abundance of miR-223 in the supernatants of stimulated monocytes was 
significantly increased after 72h of stimulation (d, n=5). The levels of miR-223 were quantified using qPCR. 
Statistical analysis by paired Student’s t-test (*p<0.05. **p<0.01. ***p<0.001). 
 
Fig. 5 miR-223 manipulation affects HDAC2 activity and expression in HPAEC  
	 13 
HPAEC were transfected with mimics or inhibitors of miR-223. After 72h of transfection total histone deacetylase 
(a) and HDAC2 (b) activity was significantly reduced in miR-223 transfected cells as compared to scrambled (scr) 
control transfection (n=5). Enzyme activity was measured using luminescent assays. The mRNA levels of HDAC2 
were assessed in HPAEC transfected with miR-223 mimics (c) and anti-miR-223 (d). Inhibition of miR-223 
yielded significantly higher mRNA expression levels of HDAC2 as compared to scrambled control transfection 
(n=5). d) Western Blotting experiments were used to quantify protein levels of HDAC2 in HPAEC transfected 
with mimics or anti-miRNA inhibitors of miR-223, respectively. After 72h of transfection enforced expression of 
miR-223 significantly lowered the protein amount of HDAC2 as compared to scrambled control transfection 
(n=5). Statistical analysis by paired Student’s t-test (*p<0.05, **p<0.01). 
 
Fig. 6 Manipulation of miR-223 alters the expression of Fractalkine 
In HPAEC, a) enforced expression of miR-223 increased the mRNA levels of Fractalkine (CX3CL1) b) whereas 
the inhibition of miR-223 lowered the levels of CX3CL1. mRNA expression after 72h of transfection was 
measured using qPCR analysis (n=5). Statistical analysis by paired Student’s t-test. 
 
Fig. 7 miR-223 expression in vivo 
a) miRNAs were isolated from paraffin embedded lung tissue specimen of mice that have been treated with 
lipopolysaccharide (LPS) to induce chronic obstructive pulmonary disease (COPD). Analysis by qPCR showed 
that the expression levels of miR-223 were significantly upregulated in LPS treated mice as compared to saline-
treated control mice (n=5). b) miRNAs were isolated from fresh total lung tissue of mice exposed to cigarette 
smoke. Analysis by qPCR demonstrated an increase in miR-223 levels in mice exposed to cigarette smoke 
compared to control mice (n=3). c) Linear regression shows a significant negative correlation between HDAC2 
and miR-223 expression levels in total lung tissue from COPD patients conducted by University Hospital Zurich 
(n=11) These findings are confirmed in d) a COPD patient cohort from the University of Groningen (n=57). 
Statistical analysis by unpaired Student’s t-test (**p<0.01) and linear regression by Pearson one-tailed correlation 
test in a 95% confidence interval (p<0.05). 
 
Fig. 8 Proposed regulatory mechanism of miR-223 in COPD 
The main components of a novel regulatory pathway in pulmonary arterial endothelial cells involve the action of 
inflammatory cytokines, miRNAs and HDAC2. Direct silencing of HDAC2 by miR-223 result in increased 
expression of the chemokine Fractalkine that, in turn, might adhere more monocytes to the endothelium. 
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